We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen’s Remicade Biosimilar Infringement Case Against Samsung Bioepis Dismissed
Janssen’s Remicade Biosimilar Infringement Case Against Samsung Bioepis Dismissed
Janssen Biotech and Samsung Bioepis jointly requested that Janssen’s patent infringement case be dismissed following the Supreme Court’s ruling earlier this year on the biosimilar approval process. The New Jersey federal court agreed to the motion last week.